SOUTH SAN FRANCISCO, Calif., Sept. 22, 2017 -- Catalyst Biosciences, Inc. (Nasdaq:CBIO) today announced that Nassim Usman, Ph.D., President and Chief Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2017 Healthcare Conference being held in New York City. The Catalyst Biosciences presentation will be held on Tuesday, September 26, 2017 at 3:30 p.m. Eastern Time.
About Catalyst
Catalyst is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications. Catalyst is focused on the field of hemostasis, including the subcutaneous prophylaxis of hemophilia and facilitating surgery in individuals with hemophilia. For more information, please visit www.catalystbiosciences.com.
Contacts: Investors: Fletcher Payne, CFO, Catalyst Biosciences 650.871.0761 [email protected] Media: Denise Powell 510.703.9491 [email protected]


Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 



